The UK and US have established a key trade agreement that will preserve zero duties on British medicine exports being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to raise funding on pharmaceuticals through the NHS. This commitment guarantees that import taxes on these vital goods will be held at nothing for a timeframe of the next three years.
This deal follows recent warnings to dramatically increase import taxes on branded pharmaceutical imports, with increases floated reaching double the cost.
"This arrangement between the Britain strengthens the global environment for innovative medicines and introduces much-needed fairness to U.S.–U.K. medicine commerce," an announcement said.
Trade Impact
Medicines are one of the UK's biggest goods shipped to the America, which is easily the primary market for major UK drugmakers.
Statistics indicate that in the year prior to last September, the UK shipped drugs valued at £11.1bn to the US. This figure made up 17.4% of total UK exports in that period.
"This agreement secures employment, stimulates funding and sets the stage for the UK to establish itself as a international leader for life sciences," a minister remarked.
Specific UK Commitments
The agreement involves several notable commitments from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new treatments to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to double overall health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates were more than twenty percent.
Industry Background
The deal follows a long-running dispute between the pharmaceutical industry and the UK government over spending levels and approval rates.
This friction were intensified by claims that American consumers were charged several times more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been halted or cancelled, while multi-billion-dollar investments have been announced toward projects in the United States.
One official publicly accepted that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a share of its total funding over the previous ten-year period.
